Drug Trial Radar · NCT07930338
First Study Evaluating the Safety and Dosage of YG-01 in Patients With Glioblastoma
Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
15
Planned (sponsor's estimate)
Start
Nov 2026
Primary completion
Apr 2028
Study completion Nov 2029
Sponsor
- Lead sponsor
- YGION Biomedical GmbHIndustry
- Sponsor type
- Industry
- First posted
- Nov 12, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a first-in-human, open-label, single-arm, dose-escalation Phase 1 clinical study evaluating the safety, tolerability, feasibility, and immunogenicity of the YG-01, a personalized neoantigen peptide-based cancer immunotherapy, in patients with diagnosed glioblastoma following standard-of-care therapy. The study will assess the safety and tolerability of repeated administrations of YG-01 and explore immune responses and clinical outcomes following treatment. The study includes sequential dose-escalation cohorts to evaluate the safety and tolerability of increasing dose levels of YG-01 and to identify a recommended dose for further clinical development.
Conditions
- Glioblastoma
Interventions
YG-01 Dose Level 1Biological
YG-01 administered subcutaneously at Dose Level 1 according to the study treatment schedule.
YG-01 Dose Level 2Biological
YG-01 administered subcutaneously at Dose Level 2 according to the study treatment schedule.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of local and systemic adverse events within 7 days following each administration of YG-01Time frame: From baseline until 7 days after each YG-01 administration.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Medical University Vienna
Vienna, Austria
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.